Orforglipron for Early Type 2 Diabetes Management
This scientific paper presents the ACHIEVE-1 trial, a phase 3 study investigating orforglipron, an oral, nonpeptide GLP-1 receptor agonist, for treating type 2 diabetes. The research evaluates its efficacy and safety as a once-daily monotherapy in adults whose type 2 diabetes is managed solely through diet and exercise. The findings demonstrate that orforglipron significantly reduces glycated hemoglobin levels and promotes body weight reduction over […]
Caloric reset driven by GLP-1 drugs could cut food volumes by over 10%
Post Content
How Your Microbiome Influences Your Dietary Recommendations
Editor’s Note: This article is a reprint. It was originally published April 21, 2024. In the ever-evolving field of bioenergetic medicine, the relationship between our diet, microbiome and overall health continues to unveil complex and intriguing connections. At the heart of this exploration is the legacy of Ray Peat, Ph.D., whose theories on sugar intake […]
China’s Sciwind’s GLP-1 shows similar weight loss to Novo’s Wegovy, study finds – Reuters
China’s Sciwind’s GLP-1 shows similar weight loss to Novo’s Wegovy, study finds Reuters
Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss
More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide. Medscape Medical News
Novel Oral GLP-1 Agent Cuts A1c, Weight in Early Diabetes
(MedPage Today) — CHICAGO — An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with early-stage type 2 diabetes, a phase III randomized trial found. Among 559 participants in ACHIEVE…
Chinese biotech showcases challenger to Eli Lilly’s obesity drug
Once approved, Sciwind Biosciences’ obesity drug ecnoglutide will compete with Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. (Reuters pic) BEIJING: An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co. Hangzhou […]
[Articles] Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
In adults with obesity or overweight without diabetes (type 1 or 2), individuals administered ecnoglutide had superior and sustained reduction in bodyweight versus placebo with a favourable safety profile, supporting its potential use for weight management.
[Comment] Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?
Obesity, overweight, and the consequences of excess adiposity continue to drive a substantial proportion of morbidity and mortality around the world. Prevention and treatment of obesity is an important strategy for preventing the development of multimorbidity.1 GLP-1 receptor monoagonists such as semaglutide2 or GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptor multiagonists such as tirzepatide3 are […]